Switch theme
Sign up to access all valuation multiples
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
2015
9.0K+
LTM Revenue $1.9B
LTM EBITDA $715M
$16.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hansoh Pharma has a last 12-month revenue (LTM) of $1.9B and a last 12-month EBITDA of $715M.
In the most recent fiscal year, Hansoh Pharma achieved revenue of $1.6B and an EBITDA of $701M.
Hansoh Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hansoh Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.9B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Profit | $1.7B | XXX | $1.4B | XXX | XXX | XXX |
| Gross Margin | 91% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | $715M | XXX | $701M | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 45% | XXX | XXX | XXX |
| EBIT | $665M | XXX | $515M | XXX | XXX | XXX |
| EBIT Margin | 35% | XXX | 33% | XXX | XXX | XXX |
| Net Profit | $658M | XXX | $558M | XXX | XXX | XXX |
| Net Margin | 34% | XXX | 36% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hansoh Pharma's stock price is HKD 26 (or $3).
Hansoh Pharma has current market cap of HKD 154B (or $19.6B), and EV of HKD 128B (or $16.4B).
See Hansoh Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.4B | $19.6B | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hansoh Pharma has market cap of $19.6B and EV of $16.4B.
Hansoh Pharma's trades at 10.5x EV/Revenue multiple, and 23.4x EV/EBITDA.
Equity research analysts estimate Hansoh Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hansoh Pharma has a P/E ratio of 32.4x.
See valuation multiples for Hansoh Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.6B | XXX | $19.6B | XXX | XXX | XXX |
| EV (current) | $16.4B | XXX | $16.4B | XXX | XXX | XXX |
| EV/Revenue | 9.3x | XXX | 10.5x | XXX | XXX | XXX |
| EV/EBITDA | 24.9x | XXX | 23.4x | XXX | XXX | XXX |
| EV/EBIT | 26.8x | XXX | 31.9x | XXX | XXX | XXX |
| EV/Gross Profit | 10.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 32.4x | XXX | 35.2x | XXX | XXX | XXX |
| EV/FCF | 29.0x | XXX | 38.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHansoh Pharma's last 12 month revenue growth is 10%
Hansoh Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Hansoh Pharma's rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hansoh Pharma's rule of X is 63% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hansoh Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 45% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | 52% | XXX | 55% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hansoh Pharma acquired XXX companies to date.
Last acquisition by Hansoh Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Hansoh Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hansoh Pharma founded? | Hansoh Pharma was founded in 2015. |
| Where is Hansoh Pharma headquartered? | Hansoh Pharma is headquartered in Hong Kong. |
| How many employees does Hansoh Pharma have? | As of today, Hansoh Pharma has 9.0K+ employees. |
| Who is the CEO of Hansoh Pharma? | Hansoh Pharma's CEO is Ms. Huijuan Zhong. |
| Is Hansoh Pharma publicy listed? | Yes, Hansoh Pharma is a public company listed on HKG. |
| What is the stock symbol of Hansoh Pharma? | Hansoh Pharma trades under 03692 ticker. |
| When did Hansoh Pharma go public? | Hansoh Pharma went public in 2019. |
| Who are competitors of Hansoh Pharma? | Similar companies to Hansoh Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hansoh Pharma? | Hansoh Pharma's current market cap is $19.6B |
| What is the current revenue of Hansoh Pharma? | Hansoh Pharma's last 12 months revenue is $1.9B. |
| What is the current revenue growth of Hansoh Pharma? | Hansoh Pharma revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Hansoh Pharma? | Current revenue multiple of Hansoh Pharma is 9.3x. |
| Is Hansoh Pharma profitable? | Yes, Hansoh Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hansoh Pharma? | Hansoh Pharma's last 12 months EBITDA is $715M. |
| What is Hansoh Pharma's EBITDA margin? | Hansoh Pharma's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Hansoh Pharma? | Current EBITDA multiple of Hansoh Pharma is 24.9x. |
| What is the current FCF of Hansoh Pharma? | Hansoh Pharma's last 12 months FCF is $614M. |
| What is Hansoh Pharma's FCF margin? | Hansoh Pharma's last 12 months FCF margin is 32%. |
| What is the current EV/FCF multiple of Hansoh Pharma? | Current FCF multiple of Hansoh Pharma is 29.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
